This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This guide examines emerging and best practices for initiating medication-assisted treatment in emergency departments. It also reviews the existing literature and science of the topic, identifies gaps in knowledge, and discusses challenges of implementation.

Consejos para adolescentes: la realidad sobre la metanfetamina

This factsheet for teens provides facts about methamphetamine. It describes short- and long-term effects and lists signs of methamphetamine use. The factsheet helps to dispel common myths about methamphetamine. Access sources cited in this factsheet.

This factsheet for teens provides facts about methamphetamine. It describes short- and long-term effects and lists signs of methamphetamine use. The factsheet helps to dispel common myths about methamphetamine. Access sources cited in this factsheet.

This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This comprehensive kit provides substance use disorder treatment professionals with a year-long intensive outpatient treatment model. Professionals can use this model when treating clients who are dependent on stimulant drugs, such as methamphetamine and cocaine.

The referenced PowerPoint Presentation Sessions are available for download.

View recommendations for related products.

This guide contains patient materials for an intensive outpatient treatment course for stimulant misuse. It provides handouts to use in individual and conjoint sessions, and sessions on early recovery skills and relapse prevention.